Protein Therapeutic Articles & Analysis
22 news found
Creative BioMart, a biotechnology company specializing in cell line development and protein production, has recently upgraded its GMP stable cell line development platform. This platform provides biopharmaceutical companies with a structured and regulatory-compliant approach to develop stable cell lines for therapeutic proteins, monoclonal ...
The topics set for the 2025 edition would highlight small-molecule drug discovery, novel modalities, and translational technologies with a particular focus on targeting protein degradation, RNA therapeutics, and precision drug delivery systems, which are all areas where BOC Sciences has built extensive expertise for years. ...
Introduction We recently sat down with one of our valued customers, Dr Alexis Rossignol (Clean Cells), to discuss his experience with VIPS PRO, our cutting-edge technology designed to streamline and enhance the early stages of cell line development. This interview provides insight into Clean Cells’ quest to automate and increase single-cell seeding while having undisputable proof ...
This cutting-edge Succinimidyl Carboxymethyl Ester branched 2ARM PEG offers a revolutionary approach to amine PEGylation, enhancing the modification of proteins and other biologics. PEGylation, the technique of attaching a PEG derivative to molecules, is crucial for improving the water solubility and biocompatibility of protein drugs. The Y-Shape PEG NHS ester ...
This is a crucial quality attribute of therapeutic protein drugs. Therefore, accurate characterization of glycosylation in biopharmaceutical processes requires the use of quantitative analytical methods. Given the significance of glycosylation in protein drugs, CD BioGlyco offers clients thorough services for characterization of glycosylation ...
Lumen Bioscience pioneered genetic engineering methods to highly express bioactive proteins in spirulina. The published research details how this platform was used to express a malaria protein antigen that can be delivered intranasally and later boosted with a simple oral booster. ...
At Cyrus, we see the AIFolds, together with protein design AI and physics-based traditional models, as the foundation models of protein engineering and design, leading to a next generation of new biologics derived either from natural proteins or fully designed from scratch. ...
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the company’s chief executive officer, Philipp Spycher, Ph.D., will be a speaker at the Next Generation Protein Therapeutics Summit hosted by Informa Connect. The presentation will highlight Araris’ proprietary linker technology, ...
Protease inhibitor is a key component of Oramed’s PODTM technology that protects therapeutic proteins in the digestive system Oramed has already been granted this patent in the United States and Japan Oramed Pharmaceuticals Inc. ...
Our proprietary approach to high-throughput functional screening is applicable to a variety of sectors and applications even beyond agriculture, including antibody, therapeutic protein, and enzyme engineering for pharmaceutical, life science, and industrial ...
This highly anticipated new technology will help accelerate and simplify the workflows of challenging analyte classes including peptides, proteins, lipids and glycans, with analysis times 5-60 times faster than conventional separation methods. ...
Thermo Fisher Scientific, the world leader in serving science, and Advanced Electrophoresis Solutions Ltd (AES), specialists in protein imaging technologies, today announced an agreement to combine essential protein separation techniques with mass spectrometry (MS) to advance therapeutic protein development through streamlined ...
Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering small protein therapeutics, today announced that they will be presenting the results of their Phase 1 study of OB-002H at the HIVR4P virtual meeting (https://www.hivr4p.org/). ...
Designed to manage the burgeoning volume and complexity of analytical data, the platform has established itself as an analytical workhorse for protein characterization in biopharmaceutical laboratories. The union of both platforms delivers on the promise of eliminating impediments to identifying and characterizing CQAs with the reliability, repeatability and speed required in ...
GC Pharma is a pioneer in vaccines and protein therapeutics and has long been dedicated to research and development of hemophilia treatments, currently developing its non-factor therapy for hemophilia A. ...
Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering small protein therapeutics, today announced that it is receiving advisory services and conditional funding from the National Research Council Industrial Research Assistance Program (NRC IRAP), to support the development of Orion’s lead compound, OB-002, ...
Feldan Therapeutics, a biotechnology company focusing on the development of therapeutics based on its intracellular delivery technology, today announced the appointment of Dr. ...
Feldan Therapeutics, a biotechnology company focusing on the development of therapeutics based on its intracellular delivery technology, today announced the appointment of Dr. ...
Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering small protein therapeutics, today announced successful completion of participant follow-up in their Phase 1 study of OB-002H which is an investigational candidate microbicide. ...
T3 is developing a proprietary protein delivery technology based on live bacteria expressing the «type 3 secretion system». The company has engineered the bacteria to grow selectively within solid tumors where they produce and deliver therapeutic proteins. T3’s lead product, called T3P-Y058-739, is expected to enter clinical ...